Puma Biotechnology, Inc.
http://www.pumabiotechnology.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Puma Biotechnology, Inc.
Pierre Fabre Continues Oncology R&D Push
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Stock Watch: The Swings And Roundabouts Of KRAS Inhibitor Competition
The era of follow-on medicinal chemistry has largely been eliminated by more comprehensive patent protection. Nowadays, investors trade on the differences in safety and efficacy for similar molecules.
China Biotech CEO Podcast: CANbridge’s Xue On Orphan Drug Coverage, Financing, Gene Therapy
While many of his peers elbowed each other to leap into oncology, James Xue decided to focus on rare diseases such as Hunter’s Syndrome. Now, 10 years after founding CANbridge, the CEO sat down for an audio interview with Scrip to offer his views on a flurry of key issues impacting orphan drug development in potentially the world's largest pharma market.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice